Aspirin cuts liver fat in trial - Harvard Gazette
Briefly

Since MASLD is estimated to affect up to a third of U.S. adults, aspirin represents an attractive potential low-cost option to prevent progression to cirrhosis or liver cancer...
Multiple noninvasive blood and imaging-based tests for liver fat, inflammation, and fibrosis all showed a similar direction of benefit that favored aspirin treatment...
Read at Harvard Gazette
[
|
]